Clinical Trials Logo

Diabetic Neuropathy Peripheral clinical trials

View clinical trials related to Diabetic Neuropathy Peripheral.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT03685253 Suspended - Clinical trials for Diabetic Neuropathy Peripheral

Nicotinamide Riboside for Diabetic Neuropathy

NiRiD
Start date: January 24, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

At the current time there is no effective disease modifying therapy for diabetic neuropathy (DN). The proposed study design employs a quantifiable early measure of DN, intraepidermal nerve fiber density (IENFD), allowing for accurate assessment of actual nerve fiber density. Preclinical data supports the use of Niagen® (3-(Aminocarbonyl)-1-β-D-ribofuranosyl-pyridinium chloride - NR) as a potential therapy for diabetic neuropathy. Phase I data indicates safety in humans. This study seeks to investigate the use of Niagen® (NR) as a potential treatment for diabetic neuropathy in subjects with type 2 diabetes mellitus or impaired glucose tolerance over a 6 month period. The endpoint measures in addition to the IENFD with determine changes in clinical and electrophysiological outcomes, quality of life and biochemical measures.